Biopharma firm Acumen's Q3 net loss narrows, beats estimates

Reuters11-12

Biopharma firm Acumen's Q3 net loss narrows, beats estimates

Overview

Acumen Q3 net income and income from operations beat analyst estimates
Company's cash expected to support operations into early 2027
R&D expenses decreased due to reduced CRO costs for ALTITUDE-AD trial

Outlook

Company expects topline results from ALTITUDE-AD study in late 2026
Company anticipates non-clinical data to inform EBD strategy in early 2026
Cash reserves expected to support operations into early 2027

Result Drivers

R&D EXPENSES - Decrease in R&D expenses attributed to reduced CRO costs for ALTITUDE-AD trial

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income	Beat	-$26.45 mln	-$35.46 mln (4 Analysts)
Q3 Income From Operations	Beat	-$26.51 mln	-$33.83 mln (4 Analysts)
Q3 Basic EPS		-$0.44
Q3 Operating Expenses		$26.51 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $9.50, about 79.3% above its November 11 closing price of $1.97

Press Release: ID:nGNX52ymd9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582375553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582375553","market":"nz","top_or_hot":-1,"title":"Biopharma firm Acumen's Q3 net loss narrows, beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm Acumen's Q3 net loss narrows, beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Acumen Q3 net income and income from operations beat analyst estimates</p></li><li><p>Company's cash expected to support operations into early 2027</p></li><li><p>R&amp;D expenses decreased due to reduced CRO costs for ALTITUDE-AD trial</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects topline results from ALTITUDE-AD study in late 2026</p></li><li><p>Company anticipates non-clinical data to inform EBD strategy in early 2026</p></li><li><p>Cash reserves expected to support operations into early 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease in R&amp;D expenses attributed to reduced CRO costs for ALTITUDE-AD trial</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$26.45 mln</p></td><td><p>-$35.46 mln (4 Analysts)</p></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Beat</p></td><td><p>-$26.51 mln</p></td><td><p>-$33.83 mln (4 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.44</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$26.51 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $9.50, about 79.3% above its November 11 closing price of $1.97</p></li></ul><p>Press Release: <span>ID:nGNX52ymd9</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma firm Acumen's Q3 net loss narrows, beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma firm Acumen's Q3 net loss narrows, beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biopharma firm Acumen's Q3 net loss narrows, beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Acumen Q3 net income and income from operations beat analyst estimates</p></li><li><p>Company's cash expected to support operations into early 2027</p></li><li><p>R&amp;D expenses decreased due to reduced CRO costs for ALTITUDE-AD trial</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects topline results from ALTITUDE-AD study in late 2026</p></li><li><p>Company anticipates non-clinical data to inform EBD strategy in early 2026</p></li><li><p>Cash reserves expected to support operations into early 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease in R&amp;D expenses attributed to reduced CRO costs for ALTITUDE-AD trial</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$26.45 mln</p></td><td><p>-$35.46 mln (4 Analysts)</p></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Beat</p></td><td><p>-$26.51 mln</p></td><td><p>-$33.83 mln (4 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.44</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$26.51 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $9.50, about 79.3% above its November 11 closing price of $1.97</p></li></ul><p>Press Release: <span>ID:nGNX52ymd9</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABOS","symbol_name":"Acumen Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D0:1","article_id":"2582375553","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582375553","pubTimestamp":1762949263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biopharma firm Acumen's Q3 net loss narrows, beats estimatesOverviewAcumen Q3 net income and income from operations beat analyst estimatesCompany's cash expected to support operations into early 2027R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABOS":"Acumen Pharmaceuticals, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"生物制药公司Acumen第三季度净亏损收窄，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":0.9},"content_text":"Biopharma firm Acumen's Q3 net loss narrows, beats estimatesOverviewAcumen Q3 net income and income from operations beat analyst estimatesCompany's cash expected to support operations into early 2027R&D expenses decreased due to reduced CRO costs for ALTITUDE-AD trialOutlookCompany expects topline results from ALTITUDE-AD study in late 2026Company anticipates non-clinical data to inform EBD strategy in early 2026Cash reserves expected to support operations into early 2027Result DriversR&D EXPENSES - Decrease in R&D expenses attributed to reduced CRO costs for ALTITUDE-AD trialKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net IncomeBeat-$26.45 mln-$35.46 mln (4 Analysts)Q3 Income From OperationsBeat-$26.51 mln-$33.83 mln (4 Analysts)Q3 Basic EPS-$0.44Q3 Operating Expenses$26.51 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $9.50, about 79.3% above its November 11 closing price of $1.97Press Release: ID:nGNX52ymd9For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582375553","isCrawlerRequest":true}